OncoMatch/Clinical Trials/NCT05320198
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Is NCT05320198 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies DISC-0974 for myelofibrosis; anemia.
Treatment: DISC-0974 — This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Myeloproliferative Neoplasm
Myelodysplastic Syndrome
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: hypomethylating agent or AML-like combination chemotherapy
Current treatment with hypomethylating agent or other acute myeloid leukemia (AML)-like combination chemotherapy or planned use within 6 months after Screening
Cannot have received: anemia-directed therapies (luspatercept, sotatercept, EPO-stimulating agent, imetelstat)
Exception: unless otherwise approved by Sponsor
Prior treatment with >3 anemia-directed therapies (unless otherwise approved by Sponsor) including: Luspatercept, Sotatercept (ACE-011), EPO-stimulating agent, Imetelstat
Lab requirements
Blood counts
Platelet count ≥25,000/µL and <1,000,000/µL; neutrophils ≥1,000/µL; total WBC count <50,000/µL at Screening
Kidney function
Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 by CKD-EPI formula
Liver function
AST and ALT <3.0x upper limit of normal (ULN) at Screening; Direct bilirubin <2x ULN at Screening. Higher levels are acceptable if attributed to ineffective erythropoiesis or Gilbert's syndrome, with approval from Sponsor.
Platelet count ≥25,000/µL and <1,000,000/µL; neutrophils ≥1,000/µL; total WBC count <50,000/µL at Screening. eGFR ≥30 mL/min/1.73 m2 by CKD-EPI formula. AST and ALT <3.0x ULN at Screening. Direct bilirubin <2x ULN at Screening.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner MD Anderson · Gilbert, Arizona
- City of Hope - Duarte · Duarte, California
- City of Hope - Lennar · Irvine, California
- University of California, San Francisco · San Francisco, California
- University of Colorado Anschutz Medical Campus · Aurora, Colorado
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05320198 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior hypomethylating agent or AML-like combination chemotherapy, anemia-directed therapies disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify